These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 2689951)

  • 1. [Acetylator phenotype in spondylarthritis ankylopoietica].
    Rojkovich B; Genti G; Borbás E; Bálint G; Gömör B
    Orv Hetil; 1989 Dec; 130(49):2639-41. PubMed ID: 2689951
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatic acetylator phenotype in diabetes mellitus.
    Ladero JM; Arrojo A; de Salamanca RE; Gomez M; Cano F; Alfonso M
    Ann Clin Res; 1982 Aug; 14(4):187-9. PubMed ID: 7168549
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Antitubercular agents: pharmacogenetic factors in the development of adverse effects].
    Ligueros M; Saavedra H; Neira S; Cruz-Coke R; Saavedra A; Kramer V; Gelman M; Nuñez A; Prieto JC
    Rev Med Chil; 1990 Jul; 118(7):727-35. PubMed ID: 2131519
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acetylator phenotyping in patients with malignant lymphomas, using caffeine as the metabolic probe.
    William BM; Abdel-tawab AM; Hassan EA; Mohamed OF
    Pol J Pharmacol; 2004; 56(4):445-9. PubMed ID: 15520499
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Direct and indirect determination of an acetylator phenotype in patients during treatment with hydralazine].
    McNair A; Kristensen MB; Angelo HR; Christensen JM
    Ugeskr Laeger; 1981 Jun; 143(27):1696-9. PubMed ID: 7292741
    [No Abstract]   [Full Text] [Related]  

  • 6. [Acetylation phenotype in patients with cancer of the bladder. Preliminary report].
    Skretowicz J; Polakowski P; Jeromin L; Zasada M; Szymańska J; Krajewska B
    Med Pr; 1988; 39(4):241-5. PubMed ID: 3237058
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Distribution pattern of acetylator phenotypes: effect of age].
    Gachályi B; Vas A; Hajös P; Káldor A
    Orv Hetil; 1984 Jan; 125(2):75-7. PubMed ID: 6694835
    [No Abstract]   [Full Text] [Related]  

  • 8. Caffeine as a potential indicator for acetylator status.
    Rankin RB; Hudson SA; Fell AF
    J Clin Pharm Ther; 1987 Feb; 12(1):47-51. PubMed ID: 3449563
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Determination of acetylator phenotype in Sri Lankans.
    Perera PL; Weerasinghe WM
    Ceylon Med J; 1987 Mar; 32(1):29-34. PubMed ID: 3690726
    [No Abstract]   [Full Text] [Related]  

  • 10. The influence of the acetylator phenotype for the clinical use of dihydralazine.
    Siegmund W; Franke G; Biebler KE; Donner I; Kallwellis R; Kairies M; Scherber A; Hüller H
    Int J Clin Pharmacol Ther Toxicol; 1985 Apr; 23 Suppl 1():S74-8. PubMed ID: 3842694
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatic acetylator phenotype in bladder cancer patients.
    Ladero JM; Kwok CK; Jara C; Fernandez L; Silmi AM; Tapia D; Uson AC
    Ann Clin Res; 1985; 17(3):96-9. PubMed ID: 4051447
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug acetylator phenotypes in newborn infants.
    Szórády I; Sánta A; Veress I
    Biol Res Pregnancy Perinatol; 1987; 8(1 1ST Half):23-5. PubMed ID: 3580445
    [TBL] [Abstract][Full Text] [Related]  

  • 13. N-acetylator phenotypes in hyperthyroidism.
    Siegmund W; Franke G; Meng S; Gothe P; Meng W
    Int J Clin Pharmacol Ther Toxicol; 1988 Aug; 26(8):397-9. PubMed ID: 3220615
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship between in vivo acetylator phenotypes and cytosolic N-acetyltransferase and O-acetyltransferase activities in human uroepithelial cells.
    Frederickson SM; Messing EM; Reznikoff CA; Swaminathan S
    Cancer Epidemiol Biomarkers Prev; 1994; 3(1):25-32. PubMed ID: 8118381
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Inactivation of drugs by acetylation].
    Walstad RA
    Tidsskr Nor Laegeforen; 1975 Jan; 95(2):100-3. PubMed ID: 1114495
    [No Abstract]   [Full Text] [Related]  

  • 16. Isoniazid acetylation phenotyping in Saudi Arabs.
    Matar KM; Mayet AY; Ayoola EA; Bawazir SA; Al-Faleh FZ; Al-Wazzan A
    J Clin Pharm Ther; 2004 Oct; 29(5):443-7. PubMed ID: 15482388
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acetylator phenotypes: effect of age.
    Gachályi B; Vas A; Hajós P; Káldor A
    Eur J Clin Pharmacol; 1984; 26(1):43-5. PubMed ID: 6714291
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Respiratory involvement in ankylosing spondylarthritis: relations to alpha-1-antitrypsin phenotypes and tobacco consumption].
    Eulry F; Marotel C; Lechevalier D; Haguenauer D; Crozes P; Magnin J
    Rev Rhum Ed Fr; 1994 Jun; 61(6):405-14. PubMed ID: 7833865
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Should the acetylator phenotype be determined when prescribing hydralazine for hypertension?
    Ramsay LE; Silas JH; Ollerenshaw JD; Tucker GT; Phillips FC; Freestone S
    Eur J Clin Pharmacol; 1984; 26(1):39-42. PubMed ID: 6714290
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Slow acetylation in mice is caused by a labile and catalytically impaired mutant N-acetyltransferase (NAT2 9).
    De Leon JH; Martell KJ; Vatsis KP; Weber WW
    Drug Metab Dispos; 1995 Dec; 23(12):1354-61. PubMed ID: 8689943
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.